GlassScriptPhysician profile
Jillian Hunt
NPI 1568744209
$115,738.64
in general payments reported to CMS, 2019-2025
27 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,613 · 2022: $47K · 2023: $44K · 2024: $14K · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $18K · Food and Beverage: $3,223 · Consulting Fee: $2,960 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,449.00 |
| Travel and Lodging | $18,219.19 |
| Food and Beverage | $3,223.30 |
| Consulting Fee | $2,960.00 |
| Education | $165.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84,907.08 | 2021-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $26,486.88 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $2,700.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $259.12 | 2022-2025 | Enhertu |
| Sanofi-Aventis U.S. LLC | $248.75 | 2022-2025 | |
| Immunocore Limited | $138.40 | 2023-2024 | Kimmtrak |
| Janssen Scientific Affairs, LLC | $133.89 | 2023 | Darzalex |
| Tempus Ai, INC | $127.04 | 2024 | |
| Genzyme Corporation | $113.05 | 2023-2025 | |
| Gilead Sciences, INC. | $67.85 | 2024-2025 | Trodelvy |
| Daiichi Sankyo INC. | $61.05 | 2023-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $58.58 | 2022 | |
| Janssen Biotech, INC. | $58.46 | 2024-2025 | Rybrevant |
| Array Biopharma INC | $44.66 | 2022-2023 | Braftovi, Lorbrena, Xalkori |
| Medtronic, INC. | $42.61 | 2024 | Intellis Adaptivestim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $40.88 | 2024 | Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $39.38 | 2022 | |
| Iovance Biotherapeutics, INC. | $35.14 | 2025 | Amtagvi |
| Novartis Pharmaceuticals Corporation | $26.36 | 2022 | |
| Foundation Medicine, INC. | $25.04 | 2023 | |
| Pfizer INC. | $22.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.54 | 2024 | Iclusig |
| Blueprint Medicines Corporation | $18.83 | 2022 | |
| G1 Therapeutics, INC. | $16.61 | 2022 | |
| Progenics Pharmaceuticals, INC. | $16.22 | 2024 | |
| Astellas Pharma US INC | $15.26 | 2023 | |
| Abbvie INC. | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.